United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - fluticasone propionate - spray - 50microgram/1dose

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - mometasone furoate, quantity: 50 microgram/actuation - spray, suspension - excipient ingredients: dispersible cellulose; citric acid monohydrate; glycerol; purified water; benzalkonium chloride; citric acid; sodium citrate dihydrate; polysorbate 80 - for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis in adults, adolescents and children between the ages of 3 and 11 years. the treatment of nasal polyps in adult patients 18 years of age and older. for the treatment of symptoms associated with acute rhinosinusitis in patients 12 years of age and older without the signs and symptoms of severe bacterial infection.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - mometasone furoate monohydrate, quantity: 51.73 microgram/actuation - spray, nasal - excipient ingredients: benzalkonium chloride; polysorbate 80; sodium citrate dihydrate; purified water; glycerol; citric acid monohydrate; microcrystalline cellulose; carmellose sodium - for the treatment of symptoms associated with seasonal allergic rhinitis and perennial allergic rhinitis and the prophylaxis of seasonal allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - azelastine hydrochloride, quantity: 0.137 mg/actuation (equivalent: azelastine, qty 0.125 mg/actuation) - spray, nasal - excipient ingredients: dibasic sodium phosphate dodecahydrate; disodium edetate; hypromellose; purified water; citric acid; sodium chloride - for the symptomatic treatment of seasonal allergic rhinitis, perennial allergic rhinitis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the mentholatum company ltd - hydroxyethyl salicylate; methyl nicotinate; methyl salicylate; ethyl salicylate - spray - 50mg/1gram ; 16mg/1gram ; 10mg/1gram ; 50mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the mentholatum company ltd - hydroxyethyl salicylate; methyl nicotinate; methyl salicylate; ethyl salicylate - spray - 50mg/1gram ; 16mg/1gram ; 10mg/1gram ; 50mg/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

the mentholatum company ltd. - methyl nicotinate; hydroxyethyl salicylate ; methyl salicylate; ethyl salicylate - cutaneous spray, solution - unknown - preparations with salicylic acid derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

the mentholatum company (ireland) limited - ethyl salicylate; hydroxyethyl salicylate ; methyl salicylate; methyl nicotinate - cutaneous spray, solution - preparations with salicylic acid derivatives

United States - English - NLM (National Library of Medicine)

emergent devices inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 2 mg in 0.1 ml - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic ef

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - non-ionic surfactant; ethyl and methyl esters of vegetable oil - emulsifiable concentrate - non-ionic surfactant emulsifiers & surfactants-noni active 116.0 g/l; ethyl and methyl esters of vegetable oil oil-plant active 700.0 g/l - adjuvant - defoliant additive | desiccant additive | fungicide additive | herbicide additive | insecticide additive | activator | additive - carrier - anti-evaporant | tank mixing | wetting agent (use as directed) | additive | adjuvant | agricultural chemical | evaporant | herbicide | herbicide application | improve penetrating properties | insecticide application | minimise antagonism | spray tank | wetter